Search research articles
Contact Us
Filters
Showing results (71-80 of 87) with videos related to
Page
of 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2018
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
A Bernard-Tessier, C Baldini, Patricia Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 12, 2018
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A R Hansen, C Massard, P A Ott, et al.
ESMO Open
|
March 7, 2022
Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
E F Nassif, J-Y Blay, C Massard, et al.
Investigational New Drugs
|
October 1, 2013
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
A Hollebecque, E Deutsch, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2021
Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients
M Aldea, L Cerbone, A Bayle, et al.
ESMO Open
|
June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)
C Parisi, M Banini, F Mantuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2021
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
A Laparra, M Kfoury, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y Loriot, A Marabelle, J P Guégan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 16, 2017
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours
A Hollebecque, R Bahleda, L Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2011
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety
C A Gomez-Roca, L Lacroix, C Massard, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 87) with videos related to
Sort By:
Page
of 9
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2018
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
A Bernard-Tessier, C Baldini, Patricia Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 12, 2018
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A R Hansen, C Massard, P A Ott, et al.
ESMO Open
|
March 7, 2022
Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
E F Nassif, J-Y Blay, C Massard, et al.
Investigational New Drugs
|
October 1, 2013
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
A Hollebecque, E Deutsch, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2021
Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients
M Aldea, L Cerbone, A Bayle, et al.
ESMO Open
|
June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)
C Parisi, M Banini, F Mantuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2021
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
A Laparra, M Kfoury, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y Loriot, A Marabelle, J P Guégan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 16, 2017
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours
A Hollebecque, R Bahleda, L Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2011
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety
C A Gomez-Roca, L Lacroix, C Massard, et al.
Page
of 9